Stockreport

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

IGC Pharma, Inc.  (IGC) 
NASDAQ:AMEX Investor Relations: igcinc.us/investor-center/overview
PDF - The Company is targeting a Phase 1 trial in 2024 - POTOMAC, Md.--(BUSINESS WIRE)--IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American: IGC) toda [Read more]